Free Trial
NASDAQ:DBVT

DBV Technologies Q3 2024 Earnings Report

DBV Technologies logo
$9.35 -0.15 (-1.58%)
Closing price 09/23/2025 04:00 PM Eastern
Extended Trading
$9.38 +0.04 (+0.37%)
As of 04:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DBV Technologies EPS Results

Actual EPS
-$0.80
Consensus EPS
-$1.90
Beat/Miss
Beat by +$1.10
One Year Ago EPS
N/A

DBV Technologies Revenue Results

Actual Revenue
$1.07 million
Expected Revenue
$1.17 million
Beat/Miss
Missed by -$100.00 thousand
YoY Revenue Growth
N/A

DBV Technologies Announcement Details

Quarter
Q3 2024
Time
After Market Closes
Conference Call Date
Wednesday, November 6, 2024
Conference Call Time
2:00AM ET

Upcoming Earnings

DBV Technologies' Q3 2025 earnings is scheduled for Wednesday, November 5, 2025, with a conference call scheduled at 2:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

DBV Technologies Earnings Headlines

DBV Technologies Announces Resignation of Board Member
Warren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the Nasdaq
New Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split the entire U.S. market in two on or before Sept 30, causing a crisis "many times worse than 2008."tc pixel
Analysts Set DBV Technologies S.A. (NASDAQ:DBVT) Target Price at $14.75
See More DBV Technologies Headlines

About DBV Technologies

DBV Technologies (NASDAQ:DBVT) SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents. Viaskin Peanut is being evaluated in global clinical trials to assess its ability to reduce allergic reactions and improve patients’ threshold of reactivity to peanut exposure. DBV is also exploring the applicability of its technologies to other food allergens, including cow’s milk and egg, as part of its long-term pipeline strategy.

Founded in 2002 and headquartered in Montrouge, France, DBV Technologies maintains research and development operations in Cambridge, Massachusetts, reflecting its transatlantic focus. The company has established alliances with academic institutions and leading allergy research centers to advance its clinical programs and expand its scientific expertise. Its development activities span North America, Europe and other regions where food allergy represents a significant public health challenge.

Under the leadership of President and Chief Executive Officer Daniel Tasse, DBV Technologies has navigated multiple phases of clinical development and regulatory interactions. The company continues to engage with health authorities to define approval pathways and to establish its proprietary immunotherapy platform as a new standard of care for allergic diseases.

View DBV Technologies Profile

More Earnings Resources from MarketBeat